ReviewWorld journal of pediatrics : WJP2026
Behçet's spectrum disorders: genetic and immunological insights into an emerging disease concept.
Review in World journal of pediatrics : WJP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBehçet's spectrum disorders (BSD) describe a conceptual framework encompassing inflammatory conditions with overlapping clinical and genetic features with Behçet's disease. First introduced in 2020, the BSD concept was proposed to contextualize BD-like inflammation in pediatric and early-onset cases by linking clinical phenotypes to shared immune pathways and supporting earlier prioritization of genetic evaluation. DATA SOURCES: A literature search was conducted in the PubMed and CNKI database using the following keywords: "Behçet's spectrum disorders", "Behçet's disease", "BD-like disease".
resultsWe found several pediatric inflammatory disorders with Behçet-like mucocutaneous, gastrointestinal, or vasculitis symptoms that overlap with Behçet disease in key immunopathogenic pathways. Based on these findings, Behçet's spectrum disorders (BSD) are conceptualized as a mechanism-oriented framework encompassing a group of immune-mediated inflammatory conditions characterized by partial overlap with Behçet disease in clinical manifestations and immunopathogenic mechanisms. Within this spectrum, disorders cluster into two tiers: core BSD comprising monogenic diseases with recurrent mucosal ulceration and direct convergence on BD-defining pathways (including haploinsufficiency of A20, RELA, or NFKB1 haploinsufficiency, and ELF4 deficiency); peripheral BSD encompassing conditions with partial clinical overlap or indirect mechanistic proximity, such as polygenic disorders (recurrent aphthous stomatitis and PFAPA), BD-like vasculitic conditions such as DADA2 (deficiency of adenosine deaminase 2), and chromosomal abnormalities exemplified by trisomy 8. Although they are often misdiagnosed as Behçet disease, these conditions are biologically separate disorders that nonetheless share similar mucosal immune dysregulation.
conclusionsThe BSD framework may help to facilitate earlier recognition and precise diagnosis of BD-related disorders in children, particularly those with atypical or syndromic presentations. The BSD framework integrates these insights to support earlier genetic screening and mechanism-guided management. However, this framework is not intended to replace current diagnostic criteria, but rather to support earlier recognition of BD-like phenotypes in children.
Indexed as
Identifiers
42337193What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.